Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Imunon stock

IMNN
US15117N6022
A3DWEJ

Price

0.87
Today +/-
+0.00
Today %
+0.03 %

Imunon stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Imunon stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Imunon stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Imunon stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Imunon's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Imunon Stock Price History

DateImunon Price
12/18/20240.87 undefined
12/17/20240.87 undefined
12/16/20240.84 undefined
12/13/20240.84 undefined
12/12/20240.85 undefined
12/11/20240.84 undefined
12/10/20240.90 undefined
12/9/20240.86 undefined
12/6/20240.84 undefined
12/5/20240.85 undefined
12/4/20240.86 undefined
12/3/20240.85 undefined
12/2/20240.87 undefined
11/29/20240.84 undefined
11/27/20240.86 undefined
11/26/20240.83 undefined
11/25/20240.81 undefined
11/22/20240.81 undefined
11/21/20240.69 undefined
11/20/20240.68 undefined
11/19/20240.69 undefined

Imunon Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Imunon, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Imunon from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Imunon’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Imunon. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Imunon’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Imunon’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Imunon’s growth potential.

Imunon Revenue, EBIT and net profit per share

DateImunon RevenueImunon EBITImunon Net Income
2029e105.66 M undefined13.46 M undefined9.61 M undefined
2028e34.1 M undefined-44.83 M undefined-4.44 M undefined
2027e7.48 M undefined-50.71 M undefined-14.79 M undefined
2026e0 undefined-37.2 M undefined-13.24 M undefined
2025e0 undefined-29.91 M undefined-16.42 M undefined
2024e0 undefined-21.28 M undefined-25.03 M undefined
20230 undefined-21.03 M undefined-19.51 M undefined
2022500,000 undefined-24.92 M undefined-35.9 M undefined
2021500,000 undefined-21.01 M undefined-20.77 M undefined
2020500,000 undefined-18.49 M undefined-21.48 M undefined
2019500,000 undefined-20.57 M undefined-16.85 M undefined
2018500,000 undefined-21.07 M undefined-11.88 M undefined
2017500,000 undefined-18.47 M undefined-20.75 M undefined
2016500,000 undefined-20.65 M undefined-22.05 M undefined
2015500,000 undefined-20.85 M undefined-22.46 M undefined
2014500,000 undefined-23.33 M undefined-25.49 M undefined
2013500,000 undefined-15.41 M undefined-12.85 M undefined
20120 undefined-22.14 M undefined-26.57 M undefined
20112 M undefined-23.02 M undefined-23.22 M undefined
20100 undefined-19.64 M undefined-18.82 M undefined
20090 undefined-17.01 M undefined-15.2 M undefined
20082.5 M undefined-11.55 M undefined-11.79 M undefined
20070 undefined-13.59 M undefined35.35 M undefined
20060 undefined-10.15 M undefined-7.58 M undefined
20050 undefined-10.37 M undefined-8.69 M undefined
20042.51 M undefined-14.6 M undefined-13.99 M undefined

Imunon Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (k)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000021100000000020002002000000000000000734105
--------50.00----------------------------------385.71208.82
------50.00100.00100.00---------50.00---50.00--50.00---------------14.292.940.95
0000001,0001,000000000000000000000000000000000000000
-3-1-1000000-1-1-3-4-2-4-7-10-13-13-8-735-11-15-18-23-26-12-25-22-22-20-11-16-21-20-35-19-25-16-13-14-49
--66.67---------200.0033.33-50.00100.0075.0042.8630.00--38.46-12.50-600.00-131.4336.3620.0027.7813.04-53.85108.33-12.00--9.09-45.0045.4531.25-4.7675.00-45.7131.58-36.00-18.757.69-71.43-325.00
0000000000000000.010.010.010.010.010.010.010.010.010.010.020.040.060.090.10.120.511.171.462.135.437.149.05000000
--------------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Imunon Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Imunon is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
19881989199019911992199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                                     
-0.02-0.010.010.10.080.010.250.270.061.368.822.510.9311.4112.2710.488.319.035.947.5212.621.5330.323.0342.8736.8620.074.324.1727.6114.8617.1649.3934.2515.7
0.090.160.10.160.630.140.150.0100000000.690.721.8815.1815000000000000000
00000010000100800090502050089000000000000000
0.260.310.230.190.270.30.270.330.040.020.0100.450.820.922.23.332.830000.130000000000000
0.020.020.020.020.040.030.030.040.080.040.060.150.050.080.360.680.442.260.260.310.610.310.960.440.680.440.190.210.090.451.351.662.452.782.55
0.350.480.360.471.020.480.710.650.181.428.92.661.5112.3113.5514.1412.8516.0221.4322.8314.121.9731.2623.4743.5537.320.264.5124.2628.0616.2118.8251.8437.0318.24
0.110.040.01000.050.030.060.030.030.120.190.210.240.390.680.570.510.270.220.540.380.781.110.831.170.850.460.180.181.841.341.170.72.35
000008.488000000000.110.0100000000000000064.50
000000000000000001.0816.180.22000000000000000
000.080.080.080.050.140.130.120.110.090.080.060.050.040.0300.070.070.060.050.040.040025.825.823.7921.0416.316.0813.4813.3700
00000000000000000000000001.981.981.981.981.981.981.98000
000000.650.4400000.030.510.440.442.082.491.241.10.360.10.080.320.61.080.240.110.110.010.262.151.91.571.621.33
0.110.040.090.080.089.238.610.190.150.140.210.30.780.730.872.93.072.917.620.860.690.51.141.711.9129.1928.7426.3423.2118.7222.0518.722.116.823.68
0.460.520.450.551.19.719.320.840.331.569.112.962.2913.0414.4217.0415.9218.9239.0523.6914.812.4732.425.1845.4666.494930.8547.4746.7838.2637.5273.9543.8521.92
                                                                     
0.140.140.150.150.160.390.410.290.40.535.821.873.451.431.481.610.110.110.110.110.130.140.340.080.140.20.230.310.170.190.230.410.060.070.09
5.335.435.635.656.3418.0218.5612.5117.2122.429.3534.7341.8967.5872.2184.5886.2287.1888.3289.1895.0499.32153.24170.96203.14229.78239.67247.88288.41294.39304.89330.29388.6397.98401.5
-7.75-8.39-9.17-9.41-8.81-10.28-12.21-15.26-19.46-21.9-26.45-33.93-43.82-57.28-60.23-74.22-82.9-90.49-55.14-66.92-82.12-100.94-124.22-156.26-169.29-195.07-218.13-241.38-261.78-273.67-290.52-312-332.77-368.67-388.18
0000000000000000000070-20-280-130-40-2000-1030400-103060.8
00000000000000000000000000000000000
-2.28-2.82-3.39-3.61-2.318.136.76-2.46-1.851.038.722.671.5211.7313.4611.973.43-3.233.2922.3713.12-1.529.0814.6533.9534.8921.776.8126.7920.9414.6418.755.8829.4113.47
0.210.160.130.10.110.230.20.611.040.130.060.150.50.880.630.8222.141.831.192.194.554.012.341.453.482.832.883.423.022.862.242.553.593.52
1.161.722.082.381.980.770.710.970.860.260.220.130.280.510.360.741.331.31.581.461.452.122.031.252.712.461.922.482.282.592.692.893.725.033.88
0.040.010.010.0300.120.11000000000.570.570.574.031.0500000.50.50.50.50.50.50.50.50.500
000000.460.331.70.280.130.12000000000000000000000000
1.341.461.621.631.3300000000000000.680.230.110.120.111.410.013.654.072.56001.841.1201.420
2.753.353.844.143.421.581.353.282.180.520.40.280.781.390.992.133.94.018.123.933.756.796.1554.6710.099.328.426.26.117.896.756.7710.047.39
0000001.2100.0100000006.1816.280.2400.180.060.073.6656.052.35009.427.963.935.854.610
00000000000000000000000000000000000
000000000000.020002.952.411.850.030.030.840.250.234.734.4817.7316.9715.714.6110.477.868.235.6301.14
0000001.2100.01000.020002.958.5918.130.270.031.020.310.38.399.4823.7819.3215.714.6119.8915.8212.1611.484.611.14
2.753.353.844.143.421.582.563.282.190.520.40.30.781.390.995.0812.4922.148.393.964.777.16.4513.3914.1533.8728.6424.1220.812623.7118.9118.2514.658.53
0.470.530.450.531.119.719.320.820.341.559.122.972.313.1214.4517.0515.9218.9441.6826.3317.895.635.5328.0448.168.7650.4130.9347.646.9438.3537.6174.1344.0622
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Imunon provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Imunon's financial health and stability.

Assets

Imunon's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Imunon must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Imunon after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Imunon's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1990199119921995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
000-1-1-3-4-2-4-6-9-13-13-8-735-11-15-18-23-26-8-25-22-22-20-11-16-21-20-35
0000000000000000000000001,000000000
000000000000000000000000000-1000
000000000000000114154-1-101-1000-1001
000000100003000-4600115-12222505310
0000000000000000000000000000004
00000000000000000000000000100000
0000-1-1-2-2-3-6-9-9-13-8-7-920-13-22-22-9-21-20-18-16-7-20-15-16-23
000000000000000-1000000000000000
000-100000000-53-313-1-15-111-299139-10-157-308
000-100000000-53-214-1-15-102-2910139-10-167-298
0000000000000000000000000000000
00001000000006900000404-3-4-290-500
000200231107191200-20625210291376390723546
000111131107191269-106252152918423610717546
0000000000000001,000000000000000000
0000000000000000000000000000000
000000017-6-110-61-1103-519-5-96-3-681-6108-8
-0.280.03-0.38-0.92-1.57-1.15-2.14-2.29-3.99-6.34-9.2-9.2-14.42-8.17-7.49-11.272.26-1.07-13.38-23.31-22.75-9.59-22.02-20.94-18.44-16.68-7.18-20.61-15.64-16.53-23.4
0000000000000000000000000000000

Imunon stock margins

The Imunon margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Imunon. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Imunon.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Imunon's sales revenue. A higher gross margin percentage indicates that the Imunon retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Imunon's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Imunon's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Imunon's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Imunon. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Imunon's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Imunon Margin History

Imunon Gross marginImunon Profit marginImunon EBIT marginImunon Profit margin
2029e16.33 %12.74 %9.1 %
2028e16.33 %-131.46 %-13.01 %
2027e16.33 %-677.95 %-197.73 %
2026e16.33 %0 %0 %
2025e16.33 %0 %0 %
2024e16.33 %0 %0 %
202316.33 %0 %0 %
202216.33 %-4,984 %-7,180 %
202116.33 %-4,202 %-4,154 %
202016.33 %-3,698 %-4,296 %
201916.33 %-4,114 %-3,370 %
201816.33 %-4,214 %-2,376 %
201716.33 %-3,694 %-4,150 %
201616.33 %-4,130 %-4,410 %
201516.33 %-4,170 %-4,492 %
201416.33 %-4,666 %-5,098 %
201316.33 %-3,082 %-2,570 %
201216.33 %0 %0 %
201116.33 %-1,151 %-1,161 %
201016.33 %0 %0 %
200916.33 %0 %0 %
200816.33 %-462 %-471.6 %
200716.33 %0 %0 %
200616.33 %0 %0 %
200516.33 %0 %0 %
200416.33 %-581.67 %-557.37 %

Imunon Stock Sales Revenue, EBIT, Earnings per Share

The Imunon earnings per share therefore indicates how much revenue Imunon has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Imunon earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Imunon's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Imunon’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Imunon's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Imunon Revenue, EBIT and net profit per share

DateImunon Sales per ShareImunon EBIT per shareImunon Earnings per Share
2029e7.29 undefined0 undefined0.66 undefined
2028e2.35 undefined0 undefined-0.31 undefined
2027e0.52 undefined0 undefined-1.02 undefined
2026e0 undefined0 undefined-0.91 undefined
2025e0 undefined0 undefined-1.13 undefined
2024e0 undefined0 undefined-1.73 undefined
20230 undefined-2.33 undefined-2.16 undefined
20220.07 undefined-3.49 undefined-5.03 undefined
20210.09 undefined-3.87 undefined-3.83 undefined
20200.23 undefined-8.68 undefined-10.08 undefined
20190.34 undefined-14.09 undefined-11.54 undefined
20180.43 undefined-18.01 undefined-10.15 undefined
20170.98 undefined-36.22 undefined-40.69 undefined
20164.17 undefined-172.08 undefined-183.75 undefined
20155 undefined-208.5 undefined-224.6 undefined
20145.56 undefined-259.22 undefined-283.22 undefined
20138.33 undefined-256.83 undefined-214.17 undefined
20120 undefined-553.5 undefined-664.25 undefined
2011100 undefined-1,151 undefined-1,161 undefined
20100 undefined-1,964 undefined-1,882 undefined
20090 undefined-1,701 undefined-1,520 undefined
2008250 undefined-1,155 undefined-1,179 undefined
20070 undefined-1,359 undefined3,535 undefined
20060 undefined-1,015 undefined-758 undefined
20050 undefined-1,037 undefined-869 undefined
2004251 undefined-1,460 undefined-1,399 undefined

Imunon business model

Imunon is one of the most popular companies on Eulerpool.com.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Imunon Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Imunon historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Imunon shares outstanding

The number of shares was Imunon in 2023 — This indicates how many shares 9.045 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Imunon earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Imunon's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Imunon’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Imunon's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Imunon stock splits

In Imunon's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Imunon.

Imunon latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.41 -0.34  (16.15 %)2024 Q3
6/30/2024-0.55 -0.51  (7.98 %)2024 Q2
3/31/2024-0.58 -0.52  (10.03 %)2024 Q1
12/31/2023-0.42 -0.52  (-24.34 %)2023 Q4
9/30/2023-0.67 -0.37  (45.04 %)2023 Q3
6/30/2023-0.72 -0.61  (15.17 %)2023 Q2
3/31/2023-0.68 -0.68  (-0.5 %)2023 Q1
12/31/2022-0.87 -1.61  (-85.7 %)2022 Q4
9/30/2022-0.83 -0.87  (-5.3 %)2022 Q3
6/30/2022-1.15 -0.87  (24.02 %)2022 Q2
1
2
3
4
5
...
6

Imunon shareholders

%
Name
Stocks
Change
Date
8.41379 % Heights Capital Management, Inc.1,220,0001,220,0007/30/2024
0.76766 % Renaissance Technologies LLC111,3115,5006/30/2024
0.51485 % Geode Capital Management, L.L.C.74,6538,0586/30/2024
0.40153 % BlackRock Institutional Trust Company, N.A.58,22206/30/2024
0.36552 % Le (Goff Corinne)53,00004/19/2024
0.33659 % The Vanguard Group, Inc.48,80606/30/2024
0.28630 % Tardugno (Michael H)41,51325,0008/15/2024
0.24138 % The Colony Group, LLC35,00006/30/2024
0.17241 % Lindborg (Stacy R. Ph.D.)25,00025,0008/15/2024
0.14692 % State Street Global Advisors (US)21,3037,0006/30/2024
1
2
3
4
...
5

Imunon Executives and Management Board

Mr. Michael Tardugno

(72)
Imunon Executive Chairman of the Board (since 2007)
Compensation 2.09 M

Dr. Corinne Le Goff

(57)
Imunon President, Chief Executive Officer, Director (since 2022)
Compensation 883,794

Dr. Khursheed Anwer

(63)
Imunon Executive Vice President, Chief Scientific Officer
Compensation 678,658

Mr. Jeffrey Church

(66)
Imunon Chief Financial Officer, Executive Vice President
Compensation 636,631

Mr. Frederick Fritz

(72)
Imunon Independent Director
Compensation 149,957
1
2

Most common questions regarding Imunon

What is the P/E ratio of Imunon 2024?

The Imunon P/E ratio is -0.31.

What is the P/S ratio of Imunon 2024?

The Imunon P/S ratio is 0.

What is the Quality Investing of Imunon?

The Quality Investing for Imunon is 2/10.

What is the revenue of Imunon 2024?

The revenue cannot currently be calculated for Imunon.

How high is the profit of Imunon 2024?

The expected Imunon profit is -25.03 M USD.

What is the business model of Imunon

No history available for Imunon.

What is the Imunon dividend?

Imunon pays a dividend of 0 USD distributed over payouts per year.

How often does Imunon pay dividends?

The dividend cannot currently be calculated for Imunon or the company does not pay out a dividend.

What is the Imunon ISIN?

The ISIN of Imunon is US15117N6022.

What is the Imunon WKN?

The WKN of Imunon is A3DWEJ.

What is the Imunon ticker?

The ticker of Imunon is IMNN.

How much dividend does Imunon pay?

Over the past 12 months, Imunon paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Imunon is expected to pay a dividend of 0 USD.

What is the dividend yield of Imunon?

The current dividend yield of Imunon is .

When does Imunon pay dividends?

Imunon pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Imunon?

Imunon paid dividends every year for the past 0 years.

What is the dividend of Imunon?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Imunon located?

Imunon is assigned to the 'Health' sector.

Wann musste ich die Aktien von Imunon kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Imunon from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Imunon pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Imunon in the year 2023?

In the year 2023, Imunon distributed 0 USD as dividends.

In which currency does Imunon pay out the dividend?

The dividends of Imunon are distributed in USD.

All fundamentals about Imunon

Our stock analysis for Imunon Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Imunon Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.